After hosting meetings with management, Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Kindred Biosciences with a $25 price target. Kindred's pipeline of novel animal health drugs will drive long-term shareholder value beyond levels currently reflected in the stock price, Folkes tells investors in a research note. He believes that the company advances its pipeline, investors should begin to appreciate the durability and peak revenue potential of the products the company brings to market. Kindred shares remain "significantly undervalued at current levels," says Folkes.